Blade Air Mobility’s Earnings Call: Growth and Strategic Moves

Blade Air Mobility, Inc. ((SRTA)) has held its Q3 earnings call. Read on for the main highlights of the call.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. The recent earnings call for Blade Air Mobility, Inc. painted a largely positive picture, with significant revenue growth and strategic transactions setting the stage for future success. The company reported strong profit margins and a promising outlook for cash flow generation. However, challenges such as the impact of the Joby transaction on stock price and ongoing legal issues were also acknowledged. Revenue Growth and Profitability The company experienced impressive year-over-year revenue growth of 29%, excluding the Keystone acquisition. This was complemented by a record segment adjusted EBITDA performance, which saw an 80% increase. The medical segment adjusted EBITDA margin also improved significantly, reaching over 15% in Q3 2025, up from 10.8% the previous year. Strategic Transactions and Rebranding Blade Air Mobility completed two major transactions: the divestiture of its passenger business and the acquisition of Keystone Perfusion. These moves were part of a broader rebranding effort, resulting in the company being renamed Strata Critical Medical and adopting a new ticker symbol, SRTA. Positive Free Cash Flow The company reported positive free cash flow from continuing operations, with expectations to maintain this trend moving forward. This is a strong indicator of the company’s financial health and its ability to sustain growth. Strong Performance in New and Existing Services Revenue from organ placement services more than doubled year-over-year, showcasing the company’s strength in both new and existing services. Additionally, a new organ logistics customer was added late in Q3, further bolstering growth prospects. Joby Transaction Stock Price Impact The earnings call highlighted a $10 million difference in cash proceeds from the Joby transaction, attributed to a significant decline in Joby’s stock price during the measurement period. This was noted as a challenge impacting financial outcomes. Legal Provision for Ongoing Litigation A legal provision was booked related to ongoing litigation from the company’s go-public transaction, as disclosed in SEC filings. This highlights ongoing legal challenges that the company is addressing. Forward-Looking Guidance During the earnings call, Strata Critical Medical provided robust guidance, forecasting a significant year-over-year revenue growth of 29%, excluding the Keystone acquisition. The company also reported an all-time high in segment adjusted EBITDA performance, with an 80% increase year-over-year. Despite a seasonal decline in transplant volumes, revenue rose 3% sequentially. The company raised its 2025 revenue guidance to $185-$195 million and reaffirmed its adjusted EBITDA guidance range of $13-$14 million, with expectations of increased medical segment adjusted EBITDA margins in Q4 2025. In conclusion, Blade Air Mobility, now Strata Critical Medical, delivered a largely positive earnings call, underscored by significant revenue growth and strategic transactions. While challenges such as the Joby transaction impact and ongoing legal issues were noted, the company’s strong financial performance and forward-looking guidance suggest a promising future.